Supplementary Materials

The following supporting information is provided: Figure S1 (plasma selenium dose–response).




Figure S1. Plasma selenium concentrations in ccRCC patients treated with 2500, 3000, 4000, 5000, and 6000 μg SLM twice daily for 14 days, then concurrently with axitinib and pembrolizumab. Selenium was measured on day 14, 2 h after each SLM dose. Plasma selenium increased in a dose-dependent manner and was significant up to 5000 μg SLM, with no evidence of selenium-attributable host toxicity. These data are pooled from and derived in part from the prior phase I dose-escalation cohort [7].